ASCO QOPI
Quality Oncology Practice Initiative

QOPI® REPORTING TRACKS

QOPI Certification	RLS[1] Tier 1	RLS Tier 2	RLS Tier 3	RLS Tier 4	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X	X	X	X	X	Core	1	Pathology report confirming malignancy	
X	X	X	X	X	Core	2	Staging documented within one month of first office visit	NQF Endorsed #0386 (adapted)
	X	X	X		Core	3	Pain assessed by second office visit	NQF Endorsed #0383/#0384 (adapted)
X		X	X	X	Core	6	Pain addressed appropriately (defect-free measure 3, 4a, 5)	NQF Endorsed #0383 (adapted)
X			X	X	Core	6a	Pain assessed on either of the two most recent office visits	NQF Endorsed #0383/#0384 (adapted)
X	X	X	X	X	Core	9	Documented plan for chemotherapy, including doses, route, and time intervals	
X		X	X	X	Core	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration	
X			X	X	Core	11	Chemotherapy intent discussion with patient documented	
	X	X	X		Core	12	Number of chemotherapy cycles documented (used in LMIC Track only)	
X				X	Core	13oc4a	Documented plan for oral chemotherapy: Dose	
X				X	Core	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration)	
X		X	X	X	Core	16	Patient consent for chemotherapy (combined measure, 14, or 15)	
X		X	X	X	Core	21aa	Smoking status/tobacco use documented in past year	NQF Endorsed #0028 (adapted)

*QOPI® Certification Measure
1) Resource-Limited Setting Track (previously called “Low-Middle Income Countries Track”)

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® REPORTING TRACKS

QOPI Certification	RLS[1] Tier 1	RLS Tier 2	RLS Tier 3	RLS Tier 4	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X			X	X	Core	24	Patient emotional well-being assessed by the second office visit	
X				X	Core	25	Action taken to address problems with emotional well-being by the second office visit	
X		X	X	X	Core	25b	Height, Weight, and BSA documented prior to chemotherapy	
X				X	Symptom/ Toxicity	30	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents	
X				X	Symptom/ Toxicity	31	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)	
X				X	Symptom/ Toxicity	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age	
			X			52a	Complete staging for patients with invasive breast cancer (Cancer stage, HER2, and ER/PR status)	
X				X	Breast	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer	NQF Endorsed #0559 (adapted)
X			X	X	Breast	54	Test for Her-2/neu overexpression or gene amplification	NQF Endorsed #1878 (adapted)
X				X	Breast	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA(T1c) and IB - III ER or PR positive breast cancer	NQF Endorsed #0220/#0387 (adapted)
X				X	Colorectal	68	Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer	NQF Endorsed #0223/#0385 (adapted)

*QOPI® Certification Measure

1) Resource-Limited Setting Track (previously called “Low-Middle Income Countries Track”)

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® REPORTING TRACKS

QOPI Certification	RLS[1] Tier 1	RLS Tier 2	RLS Tier 3	RLS Tier 4	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X				X	Colorectal	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy	NQF Endorsed #1860 (adapted)
X			X	X	NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC	
X				X	NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy	
X				X	NSCLC	89a	GCSF administered to patients who received chemotherapy for metastatic NSCLC cancer (Lower-Score- Better)	

*QOPI® Certification Measure
1) Resource-Limited Setting Track (previously called “Low-Middle Income Countries Track”)